Last reviewed · How we verify
Gentamicin Sulfate, Injectable
Gentamicin sulfate is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.
Gentamicin sulfate is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections (sepsis, urinary tract infections, respiratory tract infections), Gram-positive infections in combination therapy, Empiric therapy for suspected aerobic gram-negative infections.
At a glance
| Generic name | Gentamicin Sulfate, Injectable |
|---|---|
| Also known as | no other names, Gentamicin, Garamycin |
| Sponsor | Public Health Service of Amsterdam |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Gentamicin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA codons and preventing proper protein synthesis. This bactericidal action is particularly effective against aerobic gram-negative bacteria and some gram-positive organisms. The drug is concentration-dependent, meaning higher peak concentrations produce greater bacterial killing.
Approved indications
- Serious gram-negative bacterial infections (sepsis, urinary tract infections, respiratory tract infections)
- Gram-positive infections in combination therapy
- Empiric therapy for suspected aerobic gram-negative infections
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss, tinnitus, vertigo)
- Injection site reactions
- Neuromuscular blockade
Key clinical trials
- Intramedullary Calcium Sulfate Antibiotic Depot (PHASE3)
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia (PHASE3)
- Optimizing IV Gentamicin in JEB (PHASE1, PHASE2)
- New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (PHASE3)
- Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients (PHASE1, PHASE2)
- Antibiotic Irrigations for Intra-Abdominal Drains (PHASE2)
- Clinical Trials to Reduce the Risk of Antimicrobial Resistance (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |